SCHEMBL7614779

SCHEMBL7614779

Cc1ccc(CN[C@@H](CS)C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
LMNA P02545 1/20 0.44
NPC1 O15118 2/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
FFAR1 O14842 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2328314 1.00 ACE (0.49) ACESMN1; SMN2MEN1KMT2ALMNA
SCHEMBL8948036 1.00 ACE (0.49) ACESMN1; SMN2MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL27733929 0.98 ACE (0.48) ACESMN1; SMN2MEN1KMT2ALMNA
SCHEMBL6051729 0.87 SMN1; SMN2 (0.45) ACESMN1; SMN2MEN1KMT2ALMNA
SCHEMBL1031027 0.84 CPA3 (0.50)
SCHEMBL1109641 0.84 CPA3 (0.50)
SCHEMBL515921 0.84 CPA3 (0.50)
SCHEMBL5505220 0.83 MME (0.49) ACELMNAFFAR1
SCHEMBL1760830 0.83 ALDH1A1 (0.50) ACESMN1; SMN2KMT2ALMNANPC1
SCHEMBL29597658 0.83 ALDH1A1 (0.50) ACESMN1; SMN2KMT2ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-06-26 US claimed
EP-4493273-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES Politechnika Wroclawska (PL) 2025-01-22 EP claimed
WO-2023175356-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES POLITECHNIKA WROCLAWSKA (PL) 2023-09-21 WO claimed
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES CAMBRIDGE ENTERPRISE LIMITED (GB) 2025-06-26 US disclosed
EP-4493273-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES Politechnika Wroclawska (PL) 2025-01-22 EP disclosed
WO-2023175356-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES POLITECHNIKA WROCLAWSKA (PL) 2023-09-21 WO disclosed
EP-0497368-B1 CNP analog peptides and their use SUNTORY LTD (JP) 2002-06-12 EP disclosed
US-5571683-A HEMOCYTE LYSATE WITH ENDOTOXIN NEUTRALIZING PEPTIDES MARUHA CORPORATION (JP) 1996-11-05 US disclosed
EP-0549102-B1 Beta-glucans detection reagents and methods of detecting beta-glucans MARUHA CORP (JP) 1996-07-03 EP disclosed
US-5486596-A CYCLIC PEPTIDES CESKOSLOVENSKA AKADEMIE VED (CS) 1996-01-23 US disclosed
US-5434133-A C-type naturiuretic peptide, suppress vascular smooth muscle cell growth SUNTORY LIMITED (JP) 1995-07-18 US disclosed
EP-0549102-A1 Beta-glucans detection reagents and methods of detecting beta-glucans MARUHA CORPORATION (JP) 1993-06-30 EP disclosed
EP-0497368-A1 CNP analog peptides and their use SUNTORY LIMITED (JP) 1992-08-05 EP disclosed
EP-0231728-B1 SYNTHETIC PEPTIDE WITH HUMAN INTERLEUKIN 1 ACTIVITY SCLAVO S.p.A. (IT) 1991-05-22 EP disclosed
EP-0112149-B1 MOLECULAR CLONING AND CHARACTERIZATION OF A FURTHER GENE SEQUENCE CODING FOR HUMAN RELAXIN HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) 1991-04-10 EP disclosed
EP-0391999-A4 PEPTIDYL INHIBITORS OF THE INITIATION OF COAGULATION 1991-03-13 EP disclosed
EP-0391999-A1 PEPTIDYL INHIBITORS OF THE INITIATION OF COAGULATION CORVAS, INC. (US) 1990-10-17 EP disclosed
WO-1990003390-A1 PEPTIDYL INHIBITORS OF THE INITIATION OF COAGULATION CORVAS, INC. (US) 1990-04-05 WO disclosed
US-4774320-A IMMUNOLOGY SCLAVO S.P.A. (IT) 1988-09-27 US disclosed
EP-0231728-A2 Synthetic peptide with human interleukin 1 activity SCLAVO S.p.A. (IT) 1987-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250208137-A1 COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES F11, F2, F12 ACE 289/4885SMN1; SMN2 3707/4885MEN1 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.